Integrated Biopharma Valuation
Based on Macroaxis valuation methodology, the firm cannot be evaluated at this time. Integrated Biopharma regular Real Value cannot be determined due to lack of data. The prevalent price of Integrated Biopharma is $0.0. Our model calculates the value of Integrated Biopharma from evaluating the firm fundamentals such as Return On Equity of 0.13, return on asset of 0.0336, and Current Valuation of 12.05 M as well as inspecting its technical indicators and probability of bankruptcy. . In general, most investors encourage buying undervalued assets and selling overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Integrated Biopharma Total Value Analysis
Integrated Biopharma is currently forecasted to have valuation of 12.05 M with market capitalization of 11.2 M, debt of 53 K, and cash on hands of 343 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Integrated Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.05 M | 11.2 M | 53 K | 343 K |
Integrated Biopharma Investor Information
About 69.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. Integrated Biopharma had not issued any dividends in recent years. Based on the key measurements obtained from Integrated Biopharma's financial statements, Integrated Biopharma is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.Integrated Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Integrated Biopharma has an asset utilization ratio of 222.76 percent. This connotes that the OTC Stock is making $2.23 for each dollar of assets. An increasing asset utilization means that Integrated Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Integrated Biopharma Ownership Allocation
Integrated Biopharma has a total of 29.95 Million outstanding shares. Integrated Biopharma retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 68.58 (percent) of Integrated Biopharma outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Integrated Biopharma Profitability Analysis
The company reported the previous year's revenue of 56.25 M. Net Income was 3.84 M with profit before overhead, payroll, taxes, and interest of 6.55 M.Integrated Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Integrated Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.9 M | |
| Quarterly Earnings Growth Y O Y | -0.636 | |
| Retained Earnings | -32.3 M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |